Meeting
2022 ASCO Annual Meeting
Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma.
Authors
Yazmin Odia
Miami Cancer Institute, Baptist Health South Florida, Miami, FL
Yazmin Odia , Carl Johannes Koschmann , Rohinton Tarapore , Jeffrey Allen , Wafik Tharwat Zaky , Matthew David Hall , Doured Daghistani , Ziad Khatib , Dolly Aguilera , Tobey J. MacDonald , Peter de Blank , Susan L. McGovern , Sabine Mueller , Cassie Kline , Nicholas A. Vitanza , Joshua E. Allen , Sharon L. Gardner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03416530
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2082)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2082
Abstract #
TPS2082
Poster Bd #
415b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.
First Author: Theodore Willis Laetsch
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster
Poster
2020 ASCO Virtual Scientific Program
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
First Author: Sylvia Christine Kurz
Poster
2018 ASCO Annual Meeting
ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.
First Author: Suman Malempati